The Relationship Between the Residual Renal Function and Osteoporosis Treatment

NCT02304887 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2016-11-25

No results posted yet for this study

Summary

The relationship between osteoporosis drugs and kidney damage is unclear. In this study, we plan to reveal relationship between osteoporosis drugs and kidney damage.

Conditions

Interventions

DRUG

Bis, SERM Teriparatide, Denosumab

Osteoporotic drugs are assigned according to the disease severity, gender, age and so on.

Sponsors & Collaborators

  • Toshihiko Kono

    lead OTHER

Principal Investigators

  • Rui Niimi, MD · Tomidahama Hospital

Eligibility

Min Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-01-31
Primary Completion
2018-12-31
Completion
2019-01-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02304887 on ClinicalTrials.gov